Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Haynes, Barton F., Gilbert, Peter B., McElrath, M. Juliana, Zolla-Pazner, Susan, Tomaras, Georgia D., Alam, S. Munir, Evans, David T., Montefiori, David C., Karnasuta, Chitraporn, Sutthent, Ruengpueng, Liao, Hua-Xin, DeVico, Anthony L., Lewis, George K., Williams, Constance, Pinter, Abraham, Fong, Youyi, Janes, Holly, DeCamp, Allan, Huang, Yunda, Rao, Mangala, Billings, Erik, Karasavvas, Nicos, Robb, Merlin L., Ngauy, Viseth, de Souza, Mark S., Paris, Robert, Ferrari, Guido, Bailer, Robert T., Soderberg, Kelly A., Andrews, Charla, Berman, Phillip W., Frahm, Nicole, De Rosa, Stephen C., Alpert, Michael D., Yates, Nicole L., Shen, Xiaoying, Koup, Richard A., Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Michael, Nelson L., Kim, Jerome H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3371689/
https://ncbi.nlm.nih.gov/pubmed/22475592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1113425
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi